

## IGF-binding protein 4 (IGFBP4), His, Human

**Cat.no.** PK0208

**Product size:** 10ug 50ug 1mg

**Source:** HEK 293

**Species:** Human

**Biological Activity:** ED50 < 50 ng/ml, measured in a bioassay using FDC-P1 cells in the presence of 15ng/ml human IGF-II.

**Molecular Weight:** 30-35 kDa, observed by reducing SDS-PAGE.

**Formulation:** Lyophilized after extensive dialysis against PBS.

**Reconstitution:** Reconstituted in ddH<sub>2</sub>O or PBS at 100 µg/ml.

**Purity:** > 95% as analyzed by SDS-PAGE.

**Endotoxin Level:** < 0.2 EU/µg, determined by LAL method.

**Storage:** Lyophilized recombinant human IGFBP4 remains stable up to 6 months at lower than -70°C from date of receipt. Upon reconstitution, human IGFBP4, His should be stable up to 1 week at 4°C or up to 2 months at -20°C.

**Description:** Insulin-like growth factor-binding protein 4 (IGF-BP-4), also known as IBP-4, is a secreted glycoprotein belonging to the IGFBP family. IGF-BP-4 is produced by osteoblasts, epidermis, ovarian follicles and other tissues. It binds both insulin-like growth factor (IGF) I and II, and it circulates in the plasma in both glycosylated and non-glycosylated forms. IGF-BP-4 prolongs the half-life of the IGFs and has been shown to inhibit or stimulate the growth-promoting effects of the IGFs. Pregnancy Associated Plasma Protein A (PAPP-A) proteolytically cleaves IGF-BP-4 and reduces its affinity to bind IGFs, and thus serves as an important regulator of IGF-BP-4 function.

**Amino Acid Sequence:**

00001 DEAIHCPPCS EEKLARCRPP VGCEELVREP GCGCCATCAL  
00041 GLGMPCGVYT PRCGSLRCY PPRGVEKPLH TLMHGQGVCM  
00081 ELAEIEAIQE SLQPSDKDEG DHPNNSFSPC SAHRRCLQK  
00121 HFAKIRDRST SGGKMKVNGA PREDARVVPQ GSCQSELHRA  
00161 LERLAASQSR THEDLYIPI PNCDRNGNFH PKQCHPALDG  
00201 QRGKWCVDR KTGVKLPGGL EPKGELDCHQ LADSFREHHH  
00241 HHH

**Synonyms:** Insulin-like growth factor-binding protein 4, IBP-4, IGF-binding protein 4, IGFBP-4, IGFBP4, IBP4

**Note:** For research use only, not for use in diagnostic procedure.